NCT00360529View on ClinicalTrials.gov

24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

880

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Sexual Dysfunctions, Psychological
Interventions
DRUG

flibanserin

flibanserin placebo versus 50 mg qhs versus 100 mg qhs

Trial Locations (54)

Unknown

511.71.01034 Boehringer Ingelheim Investigational Site, Mobile

511.71.01042 Boehringer Ingelheim Investigational Site, South Birmingham

511.71.01016 Boehringer Ingelheim Investigational Site, Phoenix

511.71.01041 Boehringer Ingelheim Investigational Site, La Mesa

511.71.01011 Boehringer Ingelheim Investigational Site, San Diego

511.71.01027 Boehringer Ingelheim Investigational Site, Westlake Village

511.71.01035 Boehringer Ingelheim Investigational Site, Denver

511.71.01010 Boehringer Ingelheim Investigational Site, Groton

511.71.01021 Boehringer Ingelheim Investigational Site, New Britain

511.71.01037 Boehringer Ingelheim Investigational Site, Newark

511.71.01001 Boehringer Ingelheim Investigational Site, Boynton Beach

511.71.01032 Boehringer Ingelheim Investigational Site, Clearwater

511.71.01014 Boehringer Ingelheim Investigational Site, Miami

511.71.01025 Boehringer Ingelheim Investigational Site, Pembroke Pines

511.71.01006 Boehringer Ingelheim Investigational Site, Plantation

511.71.01015 Boehringer Ingelheim Investigational Site, Atlanta

511.71.01038 Boehringer Ingelheim Investigational Site, Marietta

511.71.01036 Boehringer Ingelheim Investigational Site, Chicago

511.71.01029 Boehringer Ingelheim Investigational Site, Evansville

511.71.01028 Boehringer Ingelheim Investigational Site, Renton

511.71.01024 Boehringer Ingelheim Investigational Site, New Orlean

511.71.01040 Boehringer Ingelheim Investigational Site, Towson

511.71.01045 Boehringer Ingelheim Investigational Site, Brighton

511.71.01005 Boehringer Ingelheim Investigational Site, St Louis

511.71.01030 Boehringer Ingelheim Investigational Site, Albuquerque

511.71.01007 Boehringer Ingelheim Investigational Site, Rochester

511.71.01012 Boehringer Ingelheim Investigational Site, The Bronx

511.71.01023 Boehringer Ingelheim Investigational Site, New Bern

511.71.01002 Boehringer Ingelheim Investigational Site, Cincinnati

511.71.01044 Boehringer Ingelheim Investigational Site, Cincinnati

511.71.01026 Boehringer Ingelheim Investigational Site, Columbus

511.71.01039 Boehringer Ingelheim Investigational Site, Edmond

511.71.01003 Boehringer Ingelheim Investigational Site, Danville

511.71.01033 Boehringer Ingelheim Investigational Site, Philadelphia

511.71.01031 Boehringer Ingelheim Investigational Site, Pittsburgh

511.71.01022 Boehringer Ingelheim Investigational Site, Mt. Pleasant

511.71.01020 Boehringer Ingelheim Investigational Site, Germantown

511.71.01017 Boehringer Ingelheim Investigational Site, San Antonio

511.71.01018 Boehringer Ingelheim Investigational Site, San Antonio

511.71.01008 Boehringer Ingelheim Investigational Site, Huntington

511.71.02002 Boehringer Ingelheim Investigational Site, Calgary

511.71.02006 Boehringer Ingelheim Investigational Site, Kelowna

511.71.02011 Boehringer Ingelheim Investigational Site, Surrey

511.71.02007 Boehringer Ingelheim Investigational Site, Vancouver

511.71.02008 Boehringer Ingelheim Investigational Site, Victoria

511.71.02012 Boehringer Ingelheim Investigational Site, Victoria

511.71.02010 Boehringer Ingelheim Investigational Site, Winnipeg

511.71.02001 Boehringer Ingelheim Investigational Site, Halifax

511.71.02004 Boehringer Ingelheim Investigational Site, Burlington

511.71.02013 Boehringer Ingelheim Investigational Site, London

511.71.02009 Boehringer Ingelheim Investigational Site, Oshawa

511.71.02003 Boehringer Ingelheim Investigational Site, Ottawa

511.71.02005 Boehringer Ingelheim Investigational Site, Montreal

511.71.02014 Boehringer Ingelheim Investigational Site, Québec

All Listed Sponsors
lead

Sprout Pharmaceuticals, Inc

INDUSTRY

NCT00360529 - 24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder | Biotech Hunter | Biotech Hunter